NCT04035096 is a Phase 1, PHASE2 clinical trial of Ascorbic Acid in Colon Cancer Stage Iv, sponsored by National Taiwan University Hospital.

Who is sponsoring NCT04035096?

NCT04035096 is sponsored by National Taiwan University Hospital.

What drugs are being tested in NCT04035096?

Interventions in NCT04035096: Ascorbic Acid, Control group.

What condition does NCT04035096 study?

NCT04035096 studies Colon Cancer Stage Iv.

Is NCT04035096 still recruiting?

NCT04035096 is currently status unknown. Last updated 29 July 2019.

Last reviewed 2019-07-29 · How we verify

NCT04035096

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effectiveness of High-dose Intravenous Vitamin c With Very Low Carbohydrate Diet for Terminal Colon Cancer Patients

Status unknown Phase 1, PHASE2 Last updated 29 July 2019

What this trial tests

Phase 1, PHASE2 trial testing Ascorbic Acid in Colon Cancer Stage Iv in 40 participants. Status unknown.

Timeline

1 January 2020

Primary endpoint
31 December 2021

30 June 2022

Quick facts

Lead sponsor	National Taiwan University Hospital
Phase	Phase 1, PHASE2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	1 January 2020
Primary completion	31 December 2021
Estimated completion	30 June 2022
Sites	1 location across Taiwan

Drugs / interventions tested

Ascorbic Acid (ASCORBIC ACID) — full drug profile →
Control group — full drug profile →

Conditions studied

Colon Cancer Stage Iv — all drugs for Colon Cancer Stage Iv →

Sponsor

National Taiwan University Hospital

Who can join

20 and older, any sex, with Colon Cancer Stage Iv. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose is to evaluate the effectiveness of high dose intravenous vitamin C (IVC) therapy plus very low carbohydrate diet (VLCD) for stage IV colon cancer (with KRAS and BRAF mutation ) with or without chemotherapy.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

The Metabolic Landscape of RAS-Driven Cancers from biology to therapy.
Mukhopadhyay S, Vander Heiden MG, McCormick F. · · 2021 · cited 212× · PMID 33870211 · DOI 10.1038/s43018-021-00184-x
Effects of dietary intervention on human diseases: molecular mechanisms and therapeutic potential.
Xiao YL, Gong Y, Qi YJ, Shao ZM, et al · · 2024 · cited 120× · PMID 38462638 · DOI 10.1038/s41392-024-01771-x
Metabolic reprogramming in colorectal cancer: regulatory networks and therapy.
Zhang J, Zou S, Fang L. · · 2023 · cited 42× · PMID 36755301 · DOI 10.1186/s13578-023-00977-w
Science-Driven Nutritional Interventions for the Prevention and Treatment of Cancer.
Montégut L, de Cabo R, Zitvogel L, Kroemer G. · · 2022 · cited 32× · PMID 35997502 · DOI 10.1158/2159-8290.cd-22-0504
Repurposing Vitamin C for Cancer Treatment: Focus on Targeting the Tumor Microenvironment.
Li WN, Zhang SJ, Feng JQ, Jin WL. · · 2022 · cited 13× · PMID 35681589 · DOI 10.3390/cancers14112608
Role of Vitamin C in Targeting Cancer Stem Cells and Cellular Plasticity.
Lee Y. · · 2023 · cited 9× · PMID 38067361 · DOI 10.3390/cancers15235657
Ras Family of Small GTPases in CRC: New Perspectives for Overcoming Drug Resistance.
Rio-Vilariño A, Del Puerto-Nevado L, García-Foncillas J, Cebrián A. · · 2021 · cited 5× · PMID 34359657 · DOI 10.3390/cancers13153757

Verify or expand the search:

Other trials of Ascorbic Acid

Trials testing the same drug.

NCT03066115 — Impact of NOS, COX, and ROS Inhibition on Cerebral Blood Flow Regulation · Phase 1 · withdrawn
NCT04138394 — VItamin C in Thermal injuRY: The VICToRY Trial · Phase 3 · suspended
NCT04354428 — Treatment for COVID-19 in High-Risk Adult Outpatients · Phase 2, PHASE3 · terminated
NCT04342728 — Coronavirus 2019 (COVID-19)- Using Ascorbic Acid and Zinc Supplementation · NA · completed
NCT04328961 — Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP) · Phase 2, PHASE3 · completed

Other National Taiwan University Hospital trials

Trials by the same sponsor.

NCT06936917 — Timing for Computed Tomography and Post-Resuscitation Care on Short-Term Outcomes in Out-of-Hospital Cardiac Arrest · not yet recruiting
NCT05396222 — A Prospective Study of the Safety and Efficacy of 3D-printed Non-rigid Biomimetic Implant in Cervical and Thoracolumbar · NA · not yet recruiting
NCT07532356 — Integrating Tumor Genomics and Urinary Exosomal Proteomics to Establish a Multi-Layer Biomarker Framework for Early Risk · not yet recruiting
NCT07317310 — The NTU JO-SMART Study · NA · not yet recruiting
NCT07382024 — Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04035096 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Taiwan University Hospital
Last refreshed: 29 July 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04035096.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing